Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 37, Status: Author

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 37, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): 3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102), decision type: , therapeutic area: , PIP number: P/0457/2022

Opinion/decision on a Paediatric investigation plan (PIP): 3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102), decision type: , therapeutic area: , PIP number: P/0457/2022

Opinion/decision on a Paediatric investigation plan (PIP): Libmeldy,atidarsagene autotemcel, decision type: , therapeutic area: , PIP number: P/0455/2022

Opinion/decision on a Paediatric investigation plan (PIP): Libmeldy,atidarsagene autotemcel, decision type: , therapeutic area: , PIP number: P/0455/2022

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia,Finerenone, decision type: , therapeutic area: , PIP number: P/0434/2022

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia,Finerenone, decision type: , therapeutic area: , PIP number: P/0434/2022

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.